Cann Pharmaceutical Australia wants to develop a multi-million dollar medical cannabis cultivation and production facility in New South Wales’ Tamworth Regional Council area.
An application for the $7.8 million project was lodged with Council early last month and accepted (not yet approved/denied) a couple of weeks later.
Cann Pharmaceutical intends establishing a 9,417m2 greenhouse, 500m2 greenhouse and 895.61m2 production facility along with various other ancillary buildings including two 20m x 12m storage sheds.
One of the proposed greenhouses would span 73m x 129m and be approximately 7.1m in height, while the other would be 25m x 20m and approximately 6.4m in height. The proposed production facility spans 21m x 41m and the manufacturing facility 12.8m x 12.3m.
The site at 37 Evans Lane, Appleby – around 21 kilometres from Tamworth – is zoned RU1 Primary Production and as the proposed development is defined as “intensive plant agriculture”, Cann Pharmaceutical believes it compatible.
“The construction and operation of the development will secure permanent and part time employment, whilst providing a product that has rapidly become an Australian identified health solution for those in need,” states documentation related to the application.
Further detail on the proposed development can be found using Tamworth Regional Council’s application tracker – the application ID is DA2021-0521.
Cann Pharmaceutical Australia was launched in 2016. The company was granted a license for Medicinal Cannabis Cultivation and Production by Australia’s Office of Drugs Control (ODC) in 2017, and a License for Medicinal Cannabis Manufacturing in 2019. The firm’s focus is on developing phyto-cannabinoid treatments for epilepsy disorders. It also has a product pipeline targeting autism, various cancers, pain, neurological conditions and terminal illnesses.
The company is engaging in a double-blind, placebo-controlled study investigating the safety, tolerability, efficacy and pharmacokinetics of an enriched cannabidiol oil called EP1 in children and adolescents with medication-resistant epilepsy. Recruitment for the trial was to have begun last year, but it doesn’t appear to have kicked off as yet. More on that study can be found here.
In other recent news from its parent company, Cann Pharmaceutical and its subsidiaries were acquired by Canndoc, operating as Intercure, last month for $35,000,000 (assumed USD). The Chairman of Intercure is Ehud Barak, who was Israel’s Prime Minister from 1999 to 2001.
